Pfizer (PFE)
Pfizer Key Statistics
Pro Data ExportCurrent Valuation
| Market Cap | 164.84B |
| Enterprise Value | 202.30B |
| PE Ratio | 17.78 |
| PE 10 Pro | Go Pro |
| PEG Ratio | 1.037 |
| Price / Sales Ratio | 2.485 |
| Price / Book Value | 1.971 |
| EV / Revenues Pro | Go Pro |
| EV / EBITDA Pro | Go Pro |
| EV / EBIT Pro | Go Pro |
| Operating Earnings Yield Pro | Go Pro |
Dividends and Shares
| Dividend | |
| Dividend Yield | 4.03% |
| Cash Div. Payout Ratio TTM Pro | Go Pro |
| Payout Ratio TTM Pro | Go Pro |
| Dividend Date | June 5, 2012 |
| Ex-Dividend Date | May 9, 2012 |
| Last Split Factor | 3.00 |
| Last Split Date | July 1, 1999 |
Profitability
| Gross Profit Margin | 80.69% |
| EBITDA Margin TTM Pro | Go Pro |
| Operating Margin TTM Pro | Go Pro |
| Profit Margin | 11.65% |
Management Effectiveness
Liquidity and Solvency
| Altman Z-Score Pro | Go Pro |
| Current Ratio | 2.025 |
| Debt to Equity Ratio | 0.4669 |
| KZ Index Pro | Go Pro |
| Tangible Common Equity Ratio Pro | Go Pro |
| Times Interest Earned TTM Pro | Go Pro |
Stock Price Performance
| Beta Pro | Go Pro |
| 1 Month Stock Returns | -4.50% |
| Year to Date Stock Returns | 1.06% |
| 1 Year Stock Returns | 1.96% |
| 3 Year Stock Returns | 43.98% |
| 52 Week High | 23.30 |
| 52 Week Low | 16.63 |
Income Statement
| Revenues TTM | 66.33B |
| Revenue Per Share TTM | 8.800 |
| Revenue Growth | -6.65% |
| Gross Profit TTM | 51.96B |
| EBITDA TTM Pro | Go Pro |
| Income from Cont. Ops Pro | Go Pro |
| Net Income TTM | 9.581B |
| Earnings Per Share TTM | 1.23 |
| Other Comprehensive Income Pro | Go Pro |
Cash Flow Statement
| Cash Investing TTM | 1.926B |
| Cash Financing TTM | -17.71B |
| Cash Operations TTM | 18.37B |
| Capital Expenditures | 254.00M |
Share Statistics
| Shares Outstanding | 7.537B |
Balance Sheet
| Cash and ST Investments | 23.97B |
| Total Assets | 185.68B |
| Liabilities | 102.01B |
| Book Value | 83.63B |
| Book Value per Share | 11.10 |
| Tangible Book Value Pro | Go Pro |
| Tangible Book Value Per Share Pro | Go Pro |
| Long Term Debt | 33.54B |
Earnings Quality
| Accruals Pro | Go Pro |
| Beneish M-Score Pro | Go Pro |
You may also be interested in these PFE related companies
PFE News
$AMRN I would be surprised if $PFE isn't having backchannel talks pre-889.$AMRN is a perfect takeout...very few employees and cinch approval
about 7 hours ago by InTheBarn
about 7 hours ago by InTheBarn
Drug Stocks In The Spotlight At ASCO Conference. $JNJ $CELG $ONXX $RHHBY $PFE http://stks.co/42e8
about 17 hours ago by abubnic
about 17 hours ago by abubnic
@SciGuy $DRRX I don't believe so; the fortunes of DURECT are tied to $PFE and Remoxy
about 20 hours ago by SlownSteady
about 20 hours ago by SlownSteady
@SCarolinaguy $DRRX licensed the drug to $PTIE; $PTIE licensed it to King and $PFE bought King; I think people might forget about $DRRX
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
@SlownSteady Sounds encouraging with $PFE supporting. What is the relationship? Surely their support would lead to approval
about 21 hours ago by SCarolinaguy
about 21 hours ago by SCarolinaguy
@SCarolinaguy $DRRX $PFE plans to resubmit the NDA. The company has other products; a recent filed trial triggered share price punishment
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
@SCarolinaguy $DRRX Only insiders know. CMC problems are usually resolved. $PFE will have new data and meet with the FDA
about 21 hours ago by SlownSteady
about 21 hours ago by SlownSteady
RT @Glopolon: Does it matter, they are next door to $PFE $AMRN /i live next to a lawyer. odds of being sued increased day they moved in. Hmm
about 4 days ago by ITradeforMe
about 4 days ago by ITradeforMe
RT @Glopolon $AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404L <Hmmmmmmmm!?$$$
about 4 days ago by Bleedblue
about 4 days ago by Bleedblue
$AMRN $PFE 'I wanna get close to you' Rose Royce http://stks.co/404H
about 4 days ago by Glopolon
about 4 days ago by Glopolon
@SomeGuy900 @christy155 $DRXX If $PFE gets a class 2 resubmission, they'll know in Q2/Q3 of next year; class one they'll know in Q1/Q2 '13
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 $DRXX The $PFE discussions with the FDA should be in Q3; I imagine they will resubmit in early 2013
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 The last comment from $DRRX management was that $PFE was getting ready to talk to the FDA about some more studies
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
@SomeGuy900 @christy155 $DRRX I have no idea what's going on. It's gone up 20 cents since I bought in. Maybe $PFE will talk with the FDA
about 5 days ago by SlownSteady
about 5 days ago by SlownSteady
Pfizer (PFE) Promotes Olivier Brandicourt to GM of Emerging Markets, Established Products Units
May 23, 7:31AM Street Insider
May 23, 7:31AM Street Insider
Pfizer (PF) Updates on Effect of Lyrica on Pain in Fibromyalgia Patients
May 18, 8:02AM Street Insider
May 18, 8:02AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PFE | 21.87 | -0.17 | -0.77% | 166.12B |
| PETM | 64.47 | +0.02 | +0.03% | 7.082B |
| PETD | 24.80 | +0.06 | +0.22% | 584.84M |
| PERY | 18.82 | -0.07 | -0.37% | 296.95M |
| PERI | 3.86 | -0.19 | -4.69% | 40.18M |
| PERF | 7.80 | -0.01 | -0.13% | 70.06M |
| PER | 19.93 | -0.07 | -0.35% | 787.60M |
| PEP | 67.99 | -0.23 | -0.34% | 108.30B |
| PEOP | 16.08 | +0.33 | +2.10% | |
| PEO | 23.01 | -0.18 | -0.78% |
